185 related articles for article (PubMed ID: 35393269)
1. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.
Deodhar AA; Combe B; Accioly AP; Bolce R; Zhu D; Gellett AM; Sprabery AT; Burmester GR
Ann Rheum Dis; 2022 Jul; 81(7):944-950. PubMed ID: 35393269
[TBL] [Abstract][Full Text] [Related]
2. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG
Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924
[TBL] [Abstract][Full Text] [Related]
3. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.
Combe B; Rahman P; Kameda H; Cañete JD; Gallo G; Agada N; Xu W; Genovese MC
Arthritis Res Ther; 2020 Jan; 22(1):14. PubMed ID: 31964419
[TBL] [Abstract][Full Text] [Related]
4. Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.
Mease P; Roussou E; Burmester GR; Goupille P; Gottlieb A; Moriarty SR; Benichou O; Adams DH; Xu W; Nash P
Arthritis Care Res (Hoboken); 2019 Mar; 71(3):367-378. PubMed ID: 30156760
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
6. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
7. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
Toussirot E
Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials.
Mease PJ; Gladman DD; Gomez-Reino JJ; Hall S; Kavanaugh A; Lespessailles E; Schett G; Paris M; Delev N; Teng L; Wollenhaupt J
ACR Open Rheumatol; 2020 Aug; 2(8):459-470. PubMed ID: 32710493
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2).
Orbai AM; Gratacós J; Turkiewicz A; Hall S; Dokoupilova E; Combe B; Nash P; Gallo G; Bertram CC; Gellett AM; Sprabery AT; Birt J; Macpherson L; Geneus VJ; Constantin A
Rheumatol Ther; 2021 Mar; 8(1):199-217. PubMed ID: 33278016
[TBL] [Abstract][Full Text] [Related]
12. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
Strober B; Leonardi C; Papp KA; Mrowietz U; Ohtsuki M; Bissonnette R; Ferris LK; Paul C; Lebwohl M; Braun DK; Mallbris L; Wilhelm S; Xu W; Ljungberg A; Acharya N; Reich K
J Am Acad Dermatol; 2017 Mar; 76(3):432-440.e17. PubMed ID: 27889292
[TBL] [Abstract][Full Text] [Related]
13. Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure.
Griffiths CEM; Gooderham M; Colombel JF; Terui T; Accioly AP; Gallo G; Zhu D; Blauvelt A
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1431-1446. PubMed ID: 35624407
[TBL] [Abstract][Full Text] [Related]
14. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
Blegvad C; Skov L; Zachariae C
Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
[No Abstract] [Full Text] [Related]
15. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P; Kirkham B; Okada M; Rahman P; Combe B; Burmester GR; Adams DH; Kerr L; Lee C; Shuler CL; Genovese M;
Lancet; 2017 Jun; 389(10086):2317-2327. PubMed ID: 28551073
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Reich K; Leonardi C; Langley RG; Warren RB; Bachelez H; Romiti R; Ohtsuki M; Xu W; Acharya N; Solotkin K; Colombel JF; Hardin DS
J Am Acad Dermatol; 2017 Mar; 76(3):441-448.e2. PubMed ID: 28027825
[TBL] [Abstract][Full Text] [Related]
18. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
[TBL] [Abstract][Full Text] [Related]
19. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
Genovese MC; Combe B; Kremer JM; Tsai TF; Behrens F; Adams DH; Lee C; Kerr L; Nash P
Rheumatology (Oxford); 2018 Nov; 57(11):2001-2011. PubMed ID: 30053162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
